Author:
Linden-Castro E.,Pelayo-Nieto M.
Publisher
Revista Mexicana de Urologia based at Sociedad Mexicana de Urologia. Colegio de Profesionales AC.
Reference13 articles.
1. Ferlay J, Bray F, Forman D, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
2. Epidemiology and risk factors of urothelial bladder cancer;Burger;Eur Urol,2013
3. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder;Babjuk;Eur Urol,2013
4. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study;Lamm;J Urol,2000
5. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate-and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance;Oddens;Eur Urol,2013